Suchergebnisse - "Verbinnen, Thierry"

PubPharm (6)

1

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

enthalten in: Virology journal | 2018

von Zoulim, F. | Moreno, C. | Lee, S. | +9

2

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation : The Phase II SATURN study

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2017

von Forns, X. | Berenguer, M. | Herzer, K. | +16

3

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea

enthalten in: Journal of gastroenterology and hepatology | 2016

von Wei, L. | Han, T. | Yang, D. | +17

4

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

enthalten in: Journal of hepatology | 2015

von Lenz, O. | Verbinnen, T. | Fevery, B. | +8

5

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN) : a randomised, double-blind, non-inferiority phase 3 trial

enthalten in: The Lancet. Infectious diseases | 2015

von Reddy, K. | Zeuzem, S. | Zoulim, F. | +14

CommentIn: Lancet Infect Dis. 2015 Jan;15(1):2-4. - PMID 25482331

6

Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy

enthalten in: Gastroenterology | 2012

von Lenz, O. | de Bruijne, J. | Vijgen, L. | +10

1
[1]